Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Lung Cancer

  Free Subscription


Articles published in Mol Cancer Ther

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    March 2020
  1. FUNAZO TY, Tsuji T, Ozasa H, Furugaki K, et al
    Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Mol Cancer Ther. 2020 Mar 26. pii: 1535-7163.MCT-19-0649.
    PubMed     Text format     Abstract available


    November 2019
  2. TANINO R, Amano Y, Tong X, Sun R, et al
    Anticancer Activity of ZnO Nanoparticles Against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model.
    Mol Cancer Ther. 2019 Nov 29. pii: 1535-7163.MCT-19-0018.
    PubMed     Text format     Abstract available


    October 2019
  3. WHALEN KA, White BH, Quinn JM, Kriksciukaite K, et al
    Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Mol Cancer Ther. 2019 Oct 24. pii: 1535-7163.MCT-19-0022.
    PubMed     Text format     Abstract available


    September 2019
  4. WANG C, Wang T, Lv D, Li L, et al
    Acquired resistance to EGFR TKIs mediated by TGF-beta1/integrin beta3 signaling in EGFR-mutant lung cancer.
    Mol Cancer Ther. 2019 Sep 9. pii: 1535-7163.MCT-19-0181.
    PubMed     Text format     Abstract available


    July 2019
  5. XU K, Sun G, Li M, Chen H, et al
    Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small-cell lung carcinoma.
    Mol Cancer Ther. 2019 Jul 24. pii: 1535-7163.MCT-18-1181.
    PubMed     Text format     Abstract available


  6. ANANTHARAJAN J, Zhou H, Zhang L, Hotz T, et al
    Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells.
    Mol Cancer Ther. 2019 Jul 8. pii: 1535-7163.MCT-18-1239.
    PubMed     Text format     Abstract available


    February 2019
  7. STAUDACHER AH, Li Y, Liapis V, Hou JJC, et al
    APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo.
    Mol Cancer Ther. 2019;18:335-345.
    PubMed     Text format     Abstract available


  8. PAPADAKI MA, Stoupis G, Theodoropoulos PA, Mavroudis D, et al
    Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Mol Cancer Ther. 2019;18:437-447.
    PubMed     Text format     Abstract available


  9. CHAI D, Shan H, Wang G, Zhang Q, et al
    Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8(+) T-cell Responses.
    Mol Cancer Ther. 2019;18:323-334.
    PubMed     Text format     Abstract available


    January 2019
  10. CHAN SH, Tsai KW, Chiu SY, Kuo WH, et al
    Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2019;18:147-161.
    PubMed     Text format     Abstract available


  11. MORENO R, Fajardo CA, Farrera-Sal M, Perise-Barrios AJ, et al
    Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.
    Mol Cancer Ther. 2019;18:127-138.
    PubMed     Text format     Abstract available


  12. NAKATANI K, Yamaoka T, Ohba M, Fujita KI, et al
    KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.
    Mol Cancer Ther. 2019;18:112-126.
    PubMed     Text format     Abstract available


  13. LEE SS, Bindokas VP, Kron SJ
    Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment.
    Mol Cancer Ther. 2019;18:213-226.
    PubMed     Text format     Abstract available


    November 2018
  14. ZERNICKEL E, Sak A, Riaz A, Klein D, et al
    Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy.
    Mol Cancer Ther. 2018 Nov 26. pii: 1535-7163.MCT-18-0067.
    PubMed     Text format     Abstract available


    October 2018
  15. ABOUBAKAR NANA F, Lecocq M, Ladjemi MZ, Detry B, et al
    Therapeutic potential of Focal Adhesion Kinase inhibition in small cell lung cancer.
    Mol Cancer Ther. 2018 Oct 23. pii: 1535-7163.MCT-18-0328.
    PubMed     Text format     Abstract available


    September 2018
  16. MOCHIZUKI S, Shimoda M, Abe H, Miyamae Y, et al
    Selective inhibition of ADAM28 suppresses lung carcinoma cell growth and metastasis.
    Mol Cancer Ther. 2018 Sep 6. pii: 1535-7163.MCT-17-1198.
    PubMed     Text format     Abstract available


    July 2018
  17. SUDA K, Murakami I, Yu H, Kim J, et al
    CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer.
    Mol Cancer Ther. 2018 Jul 26. pii: 1535-7163.MCT-17-1279.
    PubMed     Text format     Abstract available


    June 2018
  18. SHIN DH, Jo JY, Han JY
    Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer.
    Mol Cancer Ther. 2018 Jun 29. pii: 1535-7163.MCT-17-1178.
    PubMed     Text format     Abstract available


  19. NJATCHA C, Farooqui M, Kornberg A, Johnson DE, et al
    STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2018 Jun 11. pii: 1535-7163.MCT-17-1194.
    PubMed     Text format     Abstract available


    April 2018
  20. BOCKORNY B, Rusan M, Chen W, Liao RG, et al
    RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
    Mol Cancer Ther. 2018 Apr 13. pii: 1535-7163.MCT-17-0464.
    PubMed     Text format     Abstract available


    February 2018
  21. HIRANO T, Yasuda H, Hamamoto J, Nukaga S, et al
    Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
    Mol Cancer Ther. 2018 Feb 21. pii: 1535-7163.MCT-17-1033.
    PubMed     Text format     Abstract available


    October 2017
  22. YAMADA T, Amann JM, Tanimoto A, Taniguchi H, et al
    Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations.
    Mol Cancer Ther. 2017 Oct 27. pii: molcanther.0146.2017.
    PubMed     Text format     Abstract available


    August 2017
  23. AKENO N, Reece AL, Callahan M, Miller AL, et al
    Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
    Mol Cancer Ther. 2017 Aug 28. pii: molcanther.0353.2017.
    PubMed     Text format     Abstract available


  24. WATANABE S, Yoshida T, Kawakami H, Takegawa N, et al
    T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
    Mol Cancer Ther. 2017 Aug 24. pii: molcanther.0351.2017.
    PubMed     Text format     Abstract available


    July 2017
  25. SHIEN K, Papadimitrakopoulou VA, Ruder D, Behrens C, et al
    JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
    Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016.
    PubMed     Text format     Abstract available


    May 2017
  26. GAUTAM J, Ku JM, Regmi SC, Jeong H, et al
    Dual inhibition of NOX2 and receptor tyrosine kinase by BJ-1301 enhances anticancer therapy efficacy via suppression of autocrine stimulatory factors in lung cancer.
    Mol Cancer Ther. 2017 May 23. pii: molcanther.0915.2016.
    PubMed     Text format     Abstract available


  27. RAIMBOURG J, Joalland MP, Cabart M, de Plater L, et al
    Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.
    Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017.
    PubMed     Text format     Abstract available


  28. ROSS KC, Andrews AJ, Marion CD, Yen TJ, et al
    Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells.
    Mol Cancer Ther. 2017 May 12. pii: molcanther.0798.2016.
    PubMed     Text format     Abstract available


  29. LAM LT, Lin X, Faivre EJ, Yang Z, et al
    Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors.
    Mol Cancer Ther. 2017 May 3. pii: molcanther.0459.2016.
    PubMed     Text format     Abstract available


  30. CHATTERJEE S, Huang EH, Christie I, Kurland BF, et al
    Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
    Mol Cancer Ther. 2017;16:793-804.
    PubMed     Text format     Abstract available


    April 2017
  31. MANUEL-MANRESA P, Korrodi-Gregorio L, Hernando E, Villanueva A, et al
    Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0752.2016.
    PubMed     Text format     Abstract available


  32. GIMENEZ-XAVIER P, Pros E, Bonastre E, Moran S, et al
    Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0104.2017.
    PubMed     Text format     Abstract available


  33. SALGIA R
    MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
    Mol Cancer Ther. 2017;16:555-565.
    PubMed     Text format     Abstract available


    March 2017
  34. WOO JK, Jang JE, Kang JH, Seong JK, et al
    Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-Allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line.
    Mol Cancer Ther. 2017 Mar 23. pii: molcanther.0574.2016.
    PubMed     Text format     Abstract available


    January 2017
  35. HAAK AJ, Appleton KM, Lisabeth EM, Misek SA, et al
    Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
    Mol Cancer Ther. 2017;16:193-204.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: